HCV is an enveloped virion containing a single-stranded positive sense RNA genome of approximately 9,500 nucleotides. It has been identified as the major etiological agent for post-transfusion non-A and non-B hepatitis worldwide. Based on genetic similarity, HCV has been classified into six major genotypes (1-6) and numerous subtypes.
In New Zealand, approximately 56% of HCV infections are caused by genotype 1, approximately 35% due to genotype 3 and 8% due to genotype 2.3 Genotypes 4 and 6 together account for less than 2% of HCV infections, and genotype 5 does not appear to be present in New Zealand
From February 2019 a new direct-acting antiviral (DAA) oral regimen for the treatment of hepatitis C, glecaprevir + pibrentasvir (Maviret) replaced the previous treatment regimens that were HCV genotype specific. Evidence shows that 98% of patients who use the new pan-genotypic treatment Maviret and who are without cirrhosis can expect to be cured of their Hepatitis C.
Hepatitis C genotyping is still indicated for patients who have failed treatment with Maviret and in patients with decompensated cirrhosis. The test must first be approved by a microbiologist and the patient must have a current hepatits C viral load greater than 1,000 IU/mL.
Microbiology - Virology
HCIN
Dedicated EDTA tubes required, minimum 4mL whole blood
Please refer to separating guide in Additional Information section below
If sample arrives frozen, please ensure it does not thaw.
Add-on requests for genotype testing are only able to be performed if a plasma viral load has been requested. Sample volume and minimum viral load requirements must be met for sample to be tested. Please call virology on ext 80356 to discuss.
Hep C genotype
HCV genotype
2 weeks
2605